Neblair 0.63 Respules (2.5 ml Each)
Marketer
Clyde Pharmaceuticals Pvt Ltd
Salt Composition
Levosalbutamol (0.63mg/2.5ml)
Overview Neblair 0.63 Respules (2.5 ml Each)
AiroMist 0.63 units (2.5 ml vials) is a fast-acting bronchodilator, used to alleviate asthma and chronic obstructive pulmonary disease (COPD) symptoms like wheezing, coughing, and breathlessness. AiroMist provides rapid relief from respiratory distress as needed. It's typically used in conjunction with a preventative inhaler to manage symptoms long-term. Effects can persist for several hours. Use only when symptoms appear (coughing, wheezing, chest tightness, shortness of breath) or before anticipated exertion triggering breathlessness. During an asthma attack, administer the prescribed dose. Proper inhaler technique is crucial for effectiveness. Discontinue use only under physician guidance; cessation may worsen respiratory issues. Common side effects, generally mild and transient, may include: injury, bronchitis, dizziness, pain, sore throat, pharyngitis, nasal congestion, vomiting, tremors, palpitations, chest pain. Seek immediate medical attention for severe chest pain, intense headache, or significant dizziness. Before using AiroMist, inform your doctor of any high blood pressure, hyperthyroidism, cardiac history, diabetes, or hypokalemia. Disclose pregnancy or breastfeeding. Avoid driving, operating machinery, or cycling until dizziness or shakiness subsides. Smoking exacerbates lung conditions and should be avoided.
Uses of Neblair 0.63 Respules (2.5 ml Each)
Asthma and chronic obstructive pulmonary disease (COPD) management
Major Benefits of Neblair 0.63 Respules (2.5 ml Each):
Before using, carefully read the product instructions. Shake the inhaler well. Simultaneously inhale and depress the inhaler once to dispense the medicine. Retain your breath for ten seconds. Repeat the process as many times as your physician prescribed. Finally, rinse your mouth completely with water and discard the rinse water.
Common Side effects of Neblair 0.63 Respules (2.5 ml Each):
- Accidental injury
- Bronchitis (inflammation of the airways)
- Dizziness
- Pain
- Pharyngitis
- Nasal congestion (stuffy nose)
- Vomiting
- Chest pain
- Palpitations
- Sore throat
- Tremors
How to use Neblair 0.63 Respules (2.5 ml Each):
Before using, carefully read the product instructions. Agitate the inhaler well. Simultaneously, begin inhaling and depress the inhaler once to dispense the medicine. Retain your breath for ten seconds. Repeat the process until you've administered the prescribed number of inhalations. Finally, rinse your mouth completely with water and discard the rinse water.
How Neblair 0.63 Respules (2.5 ml Each) works:
Each 2.5 ml Neblair 0.63 respule provides bronchodilation, easing breathing by relaxing airway muscles and subsequently widening the breathing passages.
SAFETY ADVICE
AlcoholUNSAFE
Using Neblair 0.63 Respules (2.5 ml vials) concurrently with alcohol may induce pronounced sleepiness.
PregnancyCONSULT YOUR DOCTOR
The use of Neblair 0.63 Respules (2.5 ml each) during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the potential benefits against the risks prior to prescribing. Seek medical advice.
Breast feedingSAFE IF PRESCRIBED
Respules of Neblair 0.63 (2.5 ml each) are considered safe for use while breastfeeding. Research in humans indicates minimal to negligible transfer of the medication into breast milk, posing no known risk to the infant.
DrivingNone
No drug interactions identified.
KidneyNone
No known drug interactions.
LiverNone
No known drug interactions.
What if you forget to take Neblair 0.63 Respules (2.5 ml Each) :
Omit any missed dose of Neblair 0.63 Respules (2.5 ml each) and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Neblair 0.63 Respules (2.5 ml Each)
| Label | Value |
|---|---|
| Chemical Category | Benzyl Alcohol Derivatives |
| Developing Habits | No. |
| Type of Treatment | Breathing |
| Actions | Short-acting beta-2 agonists |




